GlycoFlux™ Human GYS2 Overexpression Jurkat Cell Line (CAT#: GLJF-0925-JF757)

Description	GlycoFlux™ human GYS2 overexpression Jurkat cell line is a stable cell line engineered to express glycogen synthase 2 (GYS2), the liver isoform catalyzing the rate-limiting step of glycogen synthesis by transferring glucose from UDP-glucose to glycogen chains. Mutations result in glycogen storage disease type 0. This model offers opportunities to investigate hepatic-type glycogen regulation and its glycosylation-linked modulation in immune cells.
Product Type	Overexpression Cell Lines
Species	Human
Cell Morphology	Suspension-growing
Passage Ratio	1:3~1:5
Cell Line	Jurkat cell line
Primary Disease	T-cell acute lymphoblastic leukemia (T-ALL)
Lineage	T Lymphocyte
Lineage Subtype	T-cell acute lymphoblastic leukemia (T-ALL)

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	qPCR, Sanger Sequencing
Culture Medium	FBS & Penicillin/Streptomycin & RPMI
Application	Mechanistic studies; Exploration of glycosylation and signaling pathways in cancer, metabolic, and immune-related diseases; Drug target validation and other functional assays.
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	GYS2
Full Name	Glycogen Synthase 2
Location	12p12.1
Gene ID	2998
Summary	The protein encoded by this gene, liver glycogen synthase, catalyzes the rate-limiting step in the synthesis of glycogen - the transfer of a glucose molecule from UDP-glucose to a terminal branch of the glycogen molecule. Mutations in this gene cause glycogen storage disease type 0 (GSD-0) - a rare type of early childhood fasting hypoglycemia with decreased liver glycogen content.